Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 7/20 | 0.40 |
| ▸ | BRAF | P15056 | 7/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25831338 | 0.83 | LRRK2 (0.33) | — | |
| SCHEMBL24009995 | 0.80 | MAPKAPK2 (0.39) | RAF1BRAF | |
| SCHEMBL187940 | 0.77 | ALDH1A1 (0.54) | — | |
| SCHEMBL25820113 | 0.76 | AAK1 (0.32) | — | |
| SCHEMBL6608296 | 0.75 | GRK6 (0.45) | PDGFRBPDGFRA | |
| SCHEMBL6789801 | 0.75 | DHFR (0.44) | — | |
| SCHEMBL8258446 | 0.74 | PDE4A (0.48) | — | |
| SCHEMBL1250505 | 0.74 | NOX1 (0.49) | — | |
| SCHEMBL3044550 | 0.74 | HSD17B10 (0.47) | — | |
| SCHEMBL705661 | 0.74 | MAPT (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | RAF1 227/4885BRAF 252/4885DOT1L 3878/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | RAF1 203/4885BRAF 231/4885DOT1L 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.